title: Hormonal replacement therapy in patients after cervical cancer treatment.
abstract: Study was made of 120 patients after surgery and/or radiotherapy for Stage I and II cervical cancer. A group of 80 patients received hormonal replacement treatment: 40 patients were treated with Trisequens (Novo)--(group T), and 40 with sequentially Dienestrol and Chlormadinon (Polfa)--(group D-Ch); the remaining 40 patients received no hormone therapy (control group). For all groups the observation time was at least 5 years. In both hormonally treated groups, evaluation was made of the effect of hormonal treatment on quality of life (intensity of climacteric complaints, postradiological changes, etc.) and on the results on oncological treatment, with special consideration of the incidence of cancer recurrence. The hormonal treatment enabled control of most climacteric symptoms, without any serious side-effects as well relieved rectal, bladder, and vaginal postradiological complications. In the whole material (120 patients) the results of oncological treatment were satisfactory. In the hormonally treated group and in controls, 5-year survival without cancer symptoms was found in 80 and 65% of cases, respectively (insignificant difference). In the hormonally treated group and in the controls, the incidence of cancer recurrences amounted to 20 and 32%, respectively (insignificant difference). The promising results of the present studies suggest the need for their continuation to aim of improving of quality of life the women treated in premenopausal age for cervical cancer.
mesh_terms: D002715:Chlormadinone Acetate / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004028:Dienestrol / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D004958:Estradiol / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000627:therapeutic use*; D004964:Estriol / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009640:Norethindrone / Q000031:analogs & derivatives / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*
chemical_list: D004338:Drug Combinations; D045166:Estradiol Congeners; D002715:Chlormadinone Acetate; D004958:Estradiol; C032040:Trisequens; D004964:Estriol; D004028:Dienestrol; D009640:Norethindrone